AXSM Axsome Therapeutics, Inc.

3.70
+0  (4%)
Previous Close 3.55
Open 3.60
Price To book 3.15
Market Cap 71.03M
Shares 19,196,000
Volume 282,969
Short Ratio 4.22
Av. Daily Volume 89,495

SEC filingsSee all SEC filings

  1. 8-K - Current report 17705040
  2. 424B5 - Prospectus (Rule 424(b)(5)) 17703779
  3. 424B5 - Prospectus (Rule 424(b)(5)) 17702328
  4. 8-K - Current report 17686886
  5. 8-K - Current report 17672949

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 to be initiated 2Q 2017.
AXS-05
Agitation in patients with Alzheimer’s disease (AD)
Initiated July 2015. Expect to complete trial by end of 2017 with interim efficacy analysis due 4Q 2017.
AXS-02 CREATE-1
Complex regional pain syndrome (CRPS)
Phase 3 initiated March 2016. Top-line data due 1Q 2018.
AXS-05 STRIDE-1
Treatment resistant depression
Phase 3 commenced March 2016. Interim analysis due 3Q 2017.
AXS-02 COAST-1
Knee Osteoarthritis Associated with Bone Marrow Lesions
Phase 3 initiation contingent upon resources.
AXS-02
Chronic Low Back Pain Associated with Modic Changes

Latest News

  1. Axsome Therapeutics to Present at the 16th Annual Needham Healthcare Conference
  2. AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  3. Axsome Therapeutics Announces Pricing of Its Public Offering of Common Stock
  4. Axsome Therapeutics Announces Proposed Public Offering of Common Stock
  5. AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  6. AXSOME THERAPEUTICS, INC. Financials
  7. Axsome reports 4Q loss
  8. Axsome reports 4Q loss
  9. AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
  10. AXSOME THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
  11. Axsome Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
  12. Axsome Therapeutics to Present at the 29th Annual ROTH Conference
  13. AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  14. Axsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Treatment Resistant Depression
  15. Axsome Therapeutics to Present at the 2017 RBC Capital Markets Global Healthcare Conference
  16. AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  17. Axsome Therapeutics to Present at the 2017 BIO CEO & Investor Conference
  18. AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  19. AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  20. Axsome Therapeutics to Present at Biotech Showcase 2017
  21. Axsome Therapeutics Receives FDA Clearance of IND for Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease Agitation
  22. AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
  23. AXSOME THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report

SEC Filings

  1. 8-K - Current report 17705040
  2. 424B5 - Prospectus (Rule 424(b)(5)) 17703779
  3. 424B5 - Prospectus (Rule 424(b)(5)) 17702328
  4. 8-K - Current report 17686886
  5. 8-K - Current report 17672949
  6. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17672646
  7. 8-K - Current report 17609631
  8. SC 13G/A (Amend) - Statement of acquisition of beneficial ownership by individuals 17604071
  9. 8-K - Current report 17589501
  10. SC 13G/A (Amend) - Statement of acquisition of beneficial ownership by individuals 17527259